NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Co-Founder Laura van ‘t Veer Wins European Cancer Organization Clinical Research Award
Significant clinical benefit of Agendia’s MammaPrint® test and other advances in the improved treatment of breast cancer recognized at ceremony during ECCO2017 IRVINE, CA and AMSTERDAM – 30 January 2017 – Agendia, Inc., a world Read More
New Data Shows that MammaPrint Substantially Impacts how Breast Cancer Patients in Germany are Treated
PRIMe trial included 452 women at 27 centers in Germany, Austria, and Switzerland Based on the outcome of the MammaPrint test, 28.4% of patients’ treatment plans were changed, compared to conventional clinico-pathological tests; preventing under Read More
Three New Studies Presented at San Antonio Breast Cancer Symposium Further Demonstrate Value of MammaPrint and BluePrint in Individualizing Treatment for Breast Cancer Patients
Long-term follow-up of early-stage breast cancer patients shows significant difference in how gene expression-based tests classify patients for adjuvant chemotherapy treatment, finds MammaPrint® the best predictor of distant cancer recurrence MINT trial confirms stratification of Read More
Agendia Responds to IQWiG Assessment for Reimbursement of Gene Expression-based Breast Cancer Recurrence Tests
IRVINE, CA and AMSTERDAM, 5 December 2016 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, notes the recommendation of Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) to delay Read More
Agendia’s MammaPrint and BluePrint Tests Highlighted in Multiple Presentations at the 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility
Agendia will also host two additional educational opportunities for physicians and patient advocates during this year’s conference IRVINE, CA and AMSTERDAM – 2, December 2016 – Agendia, Inc., a world leader in personalized medicine and Read More
Agendia’s proven breast cancer recurrence assay, MammaPrint, now available in the Middle East
Agendia signs partnership agreement with Cryogene and Mist for Middle East distribution IRVINE, CA and AMSTERDAM, 8 November 2016 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today a Read More
Agendia Announces the Award of a New Category 1 CPT Code from the American Medical Association for the MammaPrint 70-Gene Breast Cancer Recurrence Assay
The company also announces new patient awareness platform to help aid in breast cancer treatment decisions IRVINE, CA and AMSTERDAM – 1, November 2016 – Agendia, Inc., a world leader in personalized medicine and molecular Read More
